Natus Medical Files Shelf Registration Statement; Company to Issue up to $100 Million of New Common Stock

Business Wire, April 24, 2006

SAN CARLOS, Calif. -- Natus Medical Incorporated (Nasdaq:BABY) today announced that it has filed a shelf registration statement with the Securities and Exchange Commission. This registration statement would, upon its being declared effective by the Securities and Exchange Commission, register future sales of up to $100 million of Natus Common Stock. The terms of any such future offerings would be determined at the time of any future offering.

Jim Hawkins, President and Chief Executive Officer of Natus, said the Company would likely use the proceeds from any offering for general corporate purposes, including acquisitions and working capital, and to reduce debt. Natus has no specific plans to issue any securities under the registration statement at this time, and no current commitments or agreements for any specific acquisitions.

"This shelf registration statement provides us financial flexibility we need going forward," stated Hawkins.

The Company also announced that, pursuant to the exercise of contractual registration rights, it has registered 600,000 shares of Natus Common Stock that the D3 Family Funds acquired from Natus in October 2005.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Natus Medical Incorporated

Natus is a leading provider of healthcare products used for screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, newborn jaundice and newborn metabolic testing.

Additional information about Natus can be found at www.natus.com.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements regarding the intent of Natus to sell Common Stock and the potential uses of the proceeds. However, due to market conditions or otherwise, Natus may be unable or unwilling to complete any sale of securities under the shelf registration statement.

More information about potential risk factors that could affect the business and financial results of Natus is included in the registration statement on Form S-3, and Natus' annual report on Form 10-K for the year ended December 31, 2005, quarterly reports on Form 10-Q, and in other reports filed from time to time by Natus with the U.S. Securities and Exchange Commission.

A written prospectus, when available, meeting the requirements of Section 10 of the Securities Act of 1933, as amended, may be obtained from the company at 1501 Industrial Road, San Carlos, California 94070, Attention: Investor Relations.